Mirogabalin (Tarlige) in Neuropathic Pain: The Selectivity That Did Not Abolish Drowsiness
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Mirogabalin (Tarlige) in Neuropathic Pain: The Selectivity That Did Not Abolish Drowsiness

A guide to mirogabalin (Tarlige): how it differs from pregabalin at the level of the target, what studies in 1587 patients with postherpetic neuralgia and diabetic neuropathy showed, how to take it and who should see a doctor first.

Mirogabalin (Tarlige) in Neuropathic Pain: The Selectivity That Did Not Abolish Drowsiness
Neuropathic pain is pain not from damaged tissue but from a damaged wire, and ordinary painkillers barely touch it. Mirogabalin, from the pregabalin class, binds more precisely to the part of the target responsible for pain relief and stays bound to it longer. In trials in Asian patients with postherpetic neuralgia and diabetic neuropathy, pain relief is demonstrated and rises with dose.

Key points

Mirogabalin (Tarlige) is a tablet for neuropathic pain from the same class as pregabalin and gabapentin, approved in Japan and several Asian countries: it binds more precisely to the part of the target responsible for pain relief and stays bound to it longer.

SituationHow it helpsWhat human studies showed
Postherpetic neuralgia — pain after shinglescalms an over-excited nerve763 patients, up to 14 weeks: pain on a 0–10 scale fell more than on placebo — by 0.41, 0.47 and 0.77 points at 15, 20 and 30 mg a day, significant in all three groups [1]
Diabetic neuropathy and postherpetic neuralgiapain relief rises with dosepooled analysis of the two pivotal studies, 1587 patients (824 with diabetic neuropathic pain): 20 mg a day −0.31 points (95% CI −0.55 to −0.08), 30 mg −0.63 (95% CI −0.86 to −0.40) versus placebo [2]
Long-term usein a one-year study pain scores generally declinedone-year study in diabetic neuropathic pain: pain scores declined across all 52 weeks; 172 of 214 enrolled (80.4%) reached the end [3]
Precision for the targetbinds α2δ-1, linked to pain relief, and dissociates from it slowly, while leaving α2δ-2 (dizziness, drowsiness) quickly—

How it helps

What kind of pain this is

Familiar pain has a source: a wound, inflammation, a strain. The nerve reports it faithfully, and a painkiller works on the source.

Neuropathic pain is built differently. The signal carrier itself is damaged — the nerve or the pathway. There is no source in the usual sense: it hurts not because something is damaged now but because the alarm system is broken.

Hence its recognisable oddities:

▸ burning, as though the skin had been scalded;
▸ electric shocks, sudden and brief;
▸ numbness mixed with pain — an area that simultaneously feels nothing and hurts;
▸ pain from light touch — when a sheet or a sleeve becomes unbearable.

The two commonest causes are shingles, which leaves postherpetic neuralgia behind it, and diabetes, in which the long nerves of the feet and lower legs are damaged over years.

Ordinary painkillers work poorly here: there is no inflammation for them to act on. What helps are drugs that calm an over-excited nerve — and that is where this class comes in.

The class's idea: not to mask the pain but to quieten the excited wire

In a nerve ending there are calcium channels: when calcium enters through them, transmitter substances are released and the signal travels on. In a damaged nerve this machinery is disordered — there are more channels, and the signal fires on any pretext or none.

The channel has an accessory part, the α2δ subunit. Pregabalin and gabapentin bind precisely to it and reduce the excessive release of transmitters. This is not pain relief in the usual sense but turning down over-sensitive wiring.

The drug's idea: hit the right half of the target

Here the subtlety begins. The α2δ subunit exists in two forms:

▸ α2δ-1 — linked to pain relief;
▸ α2δ-2 — linked to dizziness and drowsiness.

Pregabalin binds both. Hence the logical move: build a molecule that prefers the first.

Mirogabalin is designed that way, and it has a second feature more important than the preference itself: it dissociates from α2δ-1 slowly and from α2δ-2 quickly. It lingers where it is wanted and does not linger where it is a nuisance.

The comparison that fits: if a remote has two buttons under one finger — 'turn down the pain' and 'turn down consciousness' — you can make the finger thinner, press mostly the first, and rest on it longer.

What the trials showed

Postherpetic neuralgia. A multicentre, double-blind phase 3 trial: 765 patients randomised, 763 analysed, four groups — placebo and mirogabalin at 15, 20 and 30 mg daily, for up to 14 weeks. 87.7% completed the study. The primary endpoint was the average daily pain score on a scale from 0 ('no pain') to 10 ('worst possible pain').

Pooled analysis of the two pivotal studies. Data from 1587 patients — 824 with diabetic neuropathic pain and 763 with postherpetic neuralgia, across some 350 sites in six Asian countries.

How to read 0.77 points properly

This is not the total relief the patient feels. What is measured is the difference between groups, and in pain trials improvement on placebo is substantial: people report less pain on a dummy too. A patient on the drug feels both their own improvement and the placebo component — and only what remains on top reaches the table.

How to take it

▸ The dose is raised gradually — precisely because drowsiness and dizziness are dose-dependent and usually ease as tolerance develops.
▸ Doses from the trials. In the pooled analysis, 10 mg twice daily (20 mg/day) and 15 mg twice daily (30 mg/day) gave a significant difference from placebo.
▸ Expectations must be realistic. The aim of this class is to make pain bearable, not to remove it. Expecting 'it will stop hurting' leads to disappointment and to endless dose escalation.
▸ The effect is judged in the individual over a few weeks: behind an average difference stand both those the drug helped distinctly and those it did not help at all.

Who should see a doctor first

Side effects. Across the class they are drowsiness, dizziness, oedema, weight gain; with mirogabalin, drowsiness and dizziness rise with dose:

Adverse eventPlacebo15 mg/day20 mg/day30 mg/day
Drowsiness3.8%10.8%14.5%19.1%
Dizziness2.7%5.7%9.1%13.1%

The greatest relief and the greatest drowsiness sit at the same dose. One patient in five on 30 mg a day was drowsy, and one in eight dizzy. Discontinuations for these events were uncommon: 0.6–1.9% depending on dose in the 14-week trials. But over a year in diabetic neuropathic pain, 13.1% stopped because of adverse events — one patient in eight.

▸ No driving in the first weeks, until tolerability is clear.
▸ Absence of response is a reason to stop, not to endure side effects for nothing or to continue 'just in case'.
▸ Abrupt withdrawal is undesirable across the class — tapering is discussed with the physician.

Bottom line

▸ The same class as pregabalin, but more precise for α2δ-1 and slower to leave it.
▸ Pain relief is demonstrated and rises with dose: 0.41–0.77 points out of ten against placebo.
▸ In the pooled analysis 20 and 30 mg daily gave a significant result.
▸ In diabetic neuropathic pain pain scores declined throughout the year of observation.
▸ Available only in Japan and parts of Asia.

On purchasing. There is deliberately no listing for this drug in our shop: it is approved neither in the United States nor in Europe, and the authenticity of anything sold outside the Japanese pharmacy chain cannot be vouched for. Your own pain — where it comes from and which of the available options fit — can be reviewed at a consultation.

References

1. Kato J, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160(5):1175–1185. PMID 30913164

2. Kato J, et al. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies. Clin Ther. 2021;43(5):822–835.e16. PMID 34059327

3. Baba M, et al. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020;11(3):693–698. PMID 31722446

Source: Mirogabalin (Tarlige) in Neuropathic Pain: The Selectivity That Did Not Abolish Drowsiness — universum.earth. Dr. Pereligyn.

Come back
Request a call back